Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8771293rdf:typepubmed:Citationlld:pubmed
pubmed-article:8771293lifeskim:mentionsumls-concept:C0021311lld:lifeskim
pubmed-article:8771293lifeskim:mentionsumls-concept:C1516213lld:lifeskim
pubmed-article:8771293lifeskim:mentionsumls-concept:C0026716lld:lifeskim
pubmed-article:8771293lifeskim:mentionsumls-concept:C0001180lld:lifeskim
pubmed-article:8771293lifeskim:mentionsumls-concept:C0004034lld:lifeskim
pubmed-article:8771293lifeskim:mentionsumls-concept:C0016871lld:lifeskim
pubmed-article:8771293lifeskim:mentionsumls-concept:C0369241lld:lifeskim
pubmed-article:8771293lifeskim:mentionsumls-concept:C0205281lld:lifeskim
pubmed-article:8771293lifeskim:mentionsumls-concept:C0596545lld:lifeskim
pubmed-article:8771293lifeskim:mentionsumls-concept:C0439234lld:lifeskim
pubmed-article:8771293pubmed:issue1lld:pubmed
pubmed-article:8771293pubmed:dateCreated1996-10-1lld:pubmed
pubmed-article:8771293pubmed:abstractTextTwenty systemic mold infections due to hyphic fungi (molds) arising within the last 5 years in a 60-bed cancer department are analyzed. The most frequent risk factors were plants in ward (75%), prior therapy with broad spectrum antibiotics (70%), catheter insertion (70%), acute leukemia (65%) and neutropenia (60%). Before death, a definitive diagnosis was made in 40%, and a presumptive diagnosis in 60% of patients: post mortem the presumptive antemortem diagnosis was confirmed in all cases (100% of patients). Aspergillosis was the most common invasive fungal disease (55%), followed by mucormycosis (15%), fusariosis (15%), and acremoniosis (10%). Of 20 patients, 8 (40%) were cured or improved after antifungal therapy with amphotericin B, ambisome and/or itraconazole; 8/20 (40%) died of fungal infection and 4/20 (20%) of underlying disease with fungal infection. Even though the diagnosis was made and antifungal therapy started before death in 15/ 20 (75%), invasive mold infection had a 60% overall mortality in patients with malignant disease.lld:pubmed
pubmed-article:8771293pubmed:languageenglld:pubmed
pubmed-article:8771293pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8771293pubmed:citationSubsetIMlld:pubmed
pubmed-article:8771293pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8771293pubmed:statusMEDLINElld:pubmed
pubmed-article:8771293pubmed:monthJanlld:pubmed
pubmed-article:8771293pubmed:issn0941-4355lld:pubmed
pubmed-article:8771293pubmed:authorpubmed-author:TruplJJlld:pubmed
pubmed-article:8771293pubmed:authorpubmed-author:JesenskaZZlld:pubmed
pubmed-article:8771293pubmed:authorpubmed-author:MardiakJJlld:pubmed
pubmed-article:8771293pubmed:authorpubmed-author:KrcmeryVVJrlld:pubmed
pubmed-article:8771293pubmed:authorpubmed-author:SpanikSSlld:pubmed
pubmed-article:8771293pubmed:authorpubmed-author:StudenaMMlld:pubmed
pubmed-article:8771293pubmed:authorpubmed-author:KukuckovaEElld:pubmed
pubmed-article:8771293pubmed:authorpubmed-author:KunovaEElld:pubmed
pubmed-article:8771293pubmed:issnTypePrintlld:pubmed
pubmed-article:8771293pubmed:volume4lld:pubmed
pubmed-article:8771293pubmed:ownerNLMlld:pubmed
pubmed-article:8771293pubmed:authorsCompleteYlld:pubmed
pubmed-article:8771293pubmed:pagination39-45lld:pubmed
pubmed-article:8771293pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:8771293pubmed:meshHeadingpubmed-meshheading:8771293-...lld:pubmed
pubmed-article:8771293pubmed:meshHeadingpubmed-meshheading:8771293-...lld:pubmed
pubmed-article:8771293pubmed:meshHeadingpubmed-meshheading:8771293-...lld:pubmed
pubmed-article:8771293pubmed:meshHeadingpubmed-meshheading:8771293-...lld:pubmed
pubmed-article:8771293pubmed:meshHeadingpubmed-meshheading:8771293-...lld:pubmed
pubmed-article:8771293pubmed:meshHeadingpubmed-meshheading:8771293-...lld:pubmed
pubmed-article:8771293pubmed:meshHeadingpubmed-meshheading:8771293-...lld:pubmed
pubmed-article:8771293pubmed:meshHeadingpubmed-meshheading:8771293-...lld:pubmed
pubmed-article:8771293pubmed:meshHeadingpubmed-meshheading:8771293-...lld:pubmed
pubmed-article:8771293pubmed:meshHeadingpubmed-meshheading:8771293-...lld:pubmed
pubmed-article:8771293pubmed:meshHeadingpubmed-meshheading:8771293-...lld:pubmed
pubmed-article:8771293pubmed:meshHeadingpubmed-meshheading:8771293-...lld:pubmed
pubmed-article:8771293pubmed:meshHeadingpubmed-meshheading:8771293-...lld:pubmed
pubmed-article:8771293pubmed:meshHeadingpubmed-meshheading:8771293-...lld:pubmed
pubmed-article:8771293pubmed:meshHeadingpubmed-meshheading:8771293-...lld:pubmed
pubmed-article:8771293pubmed:meshHeadingpubmed-meshheading:8771293-...lld:pubmed
pubmed-article:8771293pubmed:meshHeadingpubmed-meshheading:8771293-...lld:pubmed
pubmed-article:8771293pubmed:meshHeadingpubmed-meshheading:8771293-...lld:pubmed
pubmed-article:8771293pubmed:year1996lld:pubmed
pubmed-article:8771293pubmed:articleTitleInvasive mold infections in cancer patients: 5 years' experience with Aspergillus, Mucor, Fusarium and Acremonium infections.lld:pubmed
pubmed-article:8771293pubmed:affiliationDepartment of Medicine, University of Tranava, Slovak Republic.lld:pubmed
pubmed-article:8771293pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8771293lld:pubmed